NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $94.78M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.86M
Average 0.90M
Returns on capital
NovaBridge Biosciences management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-20.0%
avg -133.6%
ROIC
-40.2%
avg -59.2%
ROA
-17.8%
avg -97.1%
Analysis
ROA is currently the strongest return metric at -17.8% versus its period average of -97.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Cong Xu | Executive VP and Head of R&D Center of Excellence | — | 41 | — | — |
Srishti Gupta | Chief Executive Officer & Director | — | 50 | 3.00M | 5.99% |
Phillip Dennis | Chief Medical Officer | — | 63 | — | — |
Mark Hagler | President & Chief Commercial Officer | — | — | — | — |
Ming Lei | Chief Financial Officer | — | 29 | — | — |
Sean Wuxiong Cao | Chief Business Development Officer & Director | — | 59 | 266.47K | 0.53% |
Tyler Ehler | Senior Director of Investor Relations | — | — | — | — |
Wei Fu | Executive Chairman | — | 44 | 725.14K | 1.45% |
Liwei Lin | General Counsel & Board Secretary | — | 38 | — | — |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 9, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$577,300.00
Sells
7
$154,272.95
Net Transaction Value
+$423,027.05
Net buying
Most Active
Xu Cong Claire
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 18, 26Sep 18, 2026 | Dennis Phillip Andrew Direct | Sell | $5.8K$5,828.39 |
| Sep 9, 26Sep 9, 2026 | Cao Sean Wuxiong Direct | Sell | $79.9K$79,903.72 |
| Aug 31, 26Aug 31, 2026 | Xu Cong Claire Direct | Sell | $2.6K$2,592.78 |
| Jul 6, 26Jul 6, 2026 | Xu Cong Claire Direct | Sell | $4K$3,991.65 |
| Jun 18, 26Jun 18, 2026 | Dennis Phillip Andrew Direct | Sell | $5.6K$5,606.04 |
| Jun 1, 26Jun 1, 2026 | Xu Cong Claire Direct | Sell | $13.8K$13,766.36 |
| May 14, 26May 14, 2026 | Cao Sean Wuxiong Direct | Sell | $42.6K$42,584.01 |
| Apr 24, 26Apr 24, 2026 | Hagler Mark Arnold Direct | Buy | $577.3K$577,300.00 |
Summary
Insiders reported 1 buys worth $577,300.00 and 7 sells worth $154,272.95 over the last 12 months. That adds up to net buying of $423,027.05. Xu Cong Claire was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does NovaBridge Biosciences compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NBP's management, answered from reported figures.
Who manages NBP?
NovaBridge Biosciences (NBP) lists 9 active executives. The top listed executive is Cong Xu, Executive VP and Head of R&D Center of Excellence.
Are NBP insiders buying or selling?
Recent insider activity shows net buying of $13.50M.
Continue the stock analysis
Jump to another research area for this company.